COMMUNIQUÉS West-GlobeNewswire

-
Tauriga Sciences, Inc. Implements Quality Assurance Protocols Within the Manufacturing Process of its CBD Infused Gum
11/02/2019 -
Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial
11/02/2019 -
Theratechnologies Appoints General Manager in Europe
11/02/2019 -
Theratechnologies Nomme un Directeur Général en Europe
11/02/2019 -
Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
11/02/2019 -
Helix BioPharma Corp. Provides Clinical Development and Strategic Corporate Update
11/02/2019 -
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
11/02/2019 -
Nephros Appoints Alisa Lask to its Board of Directors
11/02/2019 -
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
11/02/2019 -
Arcturus Therapeutics to Present at Upcoming Investor Conferences
11/02/2019 -
Myriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs
11/02/2019 -
Resonant Inc. Provides Update on Breakthrough XBAR™ Technology for 5G Mobile Devices
11/02/2019 -
Flywheel Partners with Google Cloud to Provide Clinical Researchers with Advanced Cloud Technology and Machine Learning for Medical Imaging
11/02/2019 -
Helix TCS: A Clear Market Leader in Cannabis Ancillary Services-- CFN Media
11/02/2019 -
Surgery Partners Announces Appointment of Eric Evans as Executive Vice President and Chief Operating Officer
11/02/2019 -
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
11/02/2019 -
Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville
11/02/2019 -
Revive Closes Over 1.4 Million in Non-Brokered Private Placement
11/02/2019 -
Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
11/02/2019
Pages